Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evaxion ASEVAX -0.99%48 1-Year Share Buyback Ratio is -32.00 as of Jun. 2026. GuruFocus rates EVAX with a GF Score™ of 48/100 and a GF Value™ of $3.34 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,106 Biotechnology companies, Evaxion AS ranks worse than 67.45% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Evaxion AS's current 1-Year Share Buyback Ratio was -32.00%.
EVAX's 1-Year Share Buyback Ratio is ranked worse than 67.45% of 1106
companies
in the Biotechnology industry
Industry Median: -14.6
vs EVAX: -32.00
Evaxion AS (NAS:EVAX) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Evaxion AS 1-Year Share Buyback Ratio Related Terms
EVAX vs DYAI, ATOS, PVCT: 1-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Evaxion AS's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evaxion AS 1-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evaxion AS's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Evaxion AS's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of -32.00 mean?
Evaxion AS (EVAX) has a 1-Year Share Buyback Ratio of -32.00 as of Jun. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Evaxion AS and its competitors. According to the industry distribution chart, Evaxion AS ranks #746 out of 1106 companies in the Biotechnology industry, placing it in the top 67.5%.
Is Evaxion AS's 1-Year Share Buyback Ratio too high?
Evaxion AS's current 1-Year Share Buyback Ratio is -32.00. Based on the distribution chart, Evaxion AS ranks #746 out of 1106 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Evaxion AS has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Evaxion AS's 1-Year Share Buyback Ratio compare to DYAI and ATOS?
According to the Biotechnology industry distribution chart, Evaxion AS ranks #746 out of 1106 companies for 1-Year Share Buyback Ratio. This places Evaxion AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Evaxion AS and its competitors. Evaxion AS's current 1-Year Share Buyback Ratio is -32.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evaxion AS stock overvalued right now?
Based on GuruFocus' analysis, Evaxion AS (EVAX) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.34, compared to a current price of $3.00 — trading 10.2% below its estimated fair value. The current 1-Year Share Buyback Ratio is -32.00. Evaxion AS's overall GF Score™ is 48/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Evaxion AS (EVAX), the current 1-Year Share Buyback Ratio is -32.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evaxion AS (EVAX) Overvalued in 2026?
Based on GuruFocus' analysis, Evaxion AS stock appears to be undervalued.
The current stock price of $3.00 is trading 10.2% below its estimated GF Value™ of $3.34.
GuruFocus considers Evaxion AS to be Modestly Undervalued.
Key valuation signals for EVAX:
1-Year Share Buyback Ratio: -32.00
GF Value™: $3.34 vs. price of $3.00 (10.2% below fair value)
No single metric tells the full story. See the EVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
48GF Score
Get the complete analysis for EVAX
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVAX has been successfully added to your 
